Since the discovery of interleukin-33 (IL-33) in 2005 [1] as the ST2L ligand, the molecule has been deeply considered in inflammatory conditions, fibroproliferative diseases, autoimmune diseases, trauma, sepsis, and most recently and significantly in pulmonary and cardiovascular diseases. This evidence concerns the gene IL1RL1 and autoimmune disease.